Navigation Links
Cardiome Updates Guidance
Date:11/26/2007

ion was initiated in the first quarter of 2007. The double-blind, placebo-controlled, randomized, dose-ranging study is designed to measure the safety and efficacy of vernakalant (oral) over 90 days of oral dosing in patients at risk of recurrent atrial fibrillation, and is expected to enroll approximately 670 patients of which 500 to 600 are expected to enter the maintenance phase and be measured for efficacy.

About Cardiome Pharma Corp.

Cardiome Pharma Corp. is a product-focused cardiovascular drug development company with two late-stage clinical drug programs focused on atrial arrhythmia (intravenous and oral dosing), a Phase 1 program for GED-aPC, an engineered analog of recombinant human activated Protein C, and a pre-clinical program directed at improving cardiovascular function.

Vernakalant (iv) is the intravenous formulation of an investigational drug being evaluated for the acute conversion of atrial fibrillation (AF). Positive top-line results from two pivotal Phase 3 trials for vernakalant (iv), called ACT 1 and ACT 3, were released in December 2004 and September 2005. Cardiome's co-development partner Astellas Pharma US, Inc. submitted a New Drug Application for vernakalant (iv) in December 2006. Positive top-line results from an additional Phase 3 study evaluating patients with post-operative atrial arrhythmia, called ACT 2, were released in June 2007. An open-label safety study evaluating recent-onset AF patients, called ACT 4, has completed.

Vernakalant (oral) is being investigated as a chronic-use oral drug for the maintenance of normal heart rhythm following termination of AF. Cardiome announced positive results from a Phase 2a pilot study for vernakalant (oral) in September 2006. A Phase 2b study for vernakalant (oral) is ongoing.

In April 2007 Cardiome acquired exclusive worldwide rights for GED-aPC for all indications. Cardiome intends to initially develop GED-aPC in cardiogenic shock, a life-threatening form of
'/>"/>

SOURCE Cardiome Pharma Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Cardiome to Present at Bear Stearns Conference
2. Cardiome to Present at ThinkEquity Conference
3. Cardiome to Present at CIBC Conference
4. Cardiome To Release Third Quarter Results
5. Cardiome Initiates Phase 1 Study for GED-aPC
6. FDA Updates Prescription Guidelines for Blood Thinner
7. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
8. Cardinal Health Reaffirms Fiscal 2008 EPS Guidance, Updates Segment Profit Outlook
9. MedQuist Updates Status of Outstanding SEC Filings
10. Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Managements Internal Control Review Efforts and on Legal Proceedings
11. ADA Updates Environmental Recommendations for Handling Waste
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... pain relief targets that could be used to ... King,s College London made the discovery when researching ... of the body. , Dr Marzia Malcangio said: ... pain generation and our findings could help chemotherapy ... One potential side effect of some chemotherapy drugs ...
(Date:4/17/2014)... Diego School of Medicine report that older women, plucky ... loss are more likely to be compassionate toward strangers ... in this month,s issue of the International Journal ... associated with better health and well-being as we age, ... the outcomes of individuals whose deficits in compassion put ...
(Date:4/17/2014)... has created a new technology for modifying human ... the body and selectively target cancer and other ... that monitor and modify human physiology is a ... existing technology enabled bioengineers to build such devices ... in a customized fashion. , "The project addressed ...
(Date:4/17/2014)... NEW YORK, NY (April 16, 2014) The cause ... but a new study proposes that neurons may be ... own immune system, similar to the way autoimmune diseases ... attack the body,s cells. The study was published April ... is a new, and likely controversial, idea in Parkinson,s ...
(Date:4/17/2014)... 2014 EcoHealth Alliance, a nonprofit organization that focuses ... comprehensive review today examining the current state of knowledge ... calls for improved global surveillance strategies to combat the ... of Ebola in West Africa that has claimed the ... and Liberia. According to the World Health Organization ...
Breaking Medicine News(10 mins):Health News:New pain relief targets discovered 2Health News:The ilk of human kindness 2Health News:Building 'smart' cell-based therapies 2Health News:Is Parkinson's an autoimmune disease? 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3
... national provider of tele-health solutions, has received full accreditation from URAC ... URAC assures that SironaHealth has met all relevant standards and performs ... is timely, confidential, and includes medically appropriate care and treatment advice. ... ...
... complete medical travel packages for North American patients seeking ... ... Long Beach, Calif. (PRWEB) April 8, 2009 -- With U.S. ... trillion this year, health insurers, self-insured employers, groups and individuals are ...
... Multiple, anatomically distinct lung cancer tumors may frequently arise ... analysis of patient tumor samples published in the April ... National Cancer Institute. , Some lung cancer patients ... diagnosis. Although such multiple tumors usually share a common ...
... that the growth factor known as TGF-β is essential to ... blocking it can cause retinal dysfunction. These findings, published in ... have an important impact on the prevention and treatment of ... results are significant because they add to our understanding of ...
... testing after ,very promising, early results, , , TUESDAY, April ... radically different way of attacking prostate cancer has done ... larger-scale testing, researchers report. , One standard treatment for ... male hormones such as testosterone that help drive tumor ...
... women, not men, researchers report , , TUESDAY, April 7 ... the list of cardiac problems linked to overweight and ... however we measure it, is associated with the risk ... fellow at the Cardiovascular Epidemiology Research Unit of Beth ...
Cached Medicine News:Health News:SironaHealth Receives URAC Accreditation as a Health Call Center 2Health News:SironaHealth Receives URAC Accreditation as a Health Call Center 3Health News:Reducing Costs, Not Care: Medical Travel to New Zealand Can Help Alleviate Rising U.S. Healthcare Expenses for Insurers and Self-funded Employers 2Health News:Reducing Costs, Not Care: Medical Travel to New Zealand Can Help Alleviate Rising U.S. Healthcare Expenses for Insurers and Self-funded Employers 3Health News:Reducing Costs, Not Care: Medical Travel to New Zealand Can Help Alleviate Rising U.S. Healthcare Expenses for Insurers and Self-funded Employers 4Health News:Multifocal lung cancers appear to originate from single cancer clone 2Health News:Growth factor TGF-B helps maintain health of retinal blood vessels 2Health News:New Prostate Cancer Drug May Hold Promise 2Health News:New Prostate Cancer Drug May Hold Promise 3Health News:Obesity Linked to Heart Failure Risk 2
(Date:1/15/2014)... R.I. , Jan. 15, 2014 MultiCell Technologies, ... filed a U.S. provisional patent application concerning composition of ... to achieve targeted tumor cell death.  ... small noncoding double stranded RNA molecules (VSRNAs) which interfere ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... and Market Analysis to 2022 ... Dermatitis - India Drug Forecast and Market ...
(Date:1/15/2014)... novel wearable injector slightly larger than an Oreo cookie may ... prescription drugs in the large doses required to treat a ... and genetic disorders.  An emerging biologic drugs ... to analysts.   Many of these drugs will require a new ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... unique DHEA-S-7kits feature a ... against the C-7 position ... with no cross-reactivity with ... RIA has been optimized ...
... based on the competition principle and the ... present in the sample and a fixed ... compete for the binding sites of a ... After one hour incubation the microtiterplate is ...
Inquire...
... It is a compact Latex based reagent kit ... well as to determine the level of RF ... patient sera. The kit includes antigen coated fine ... control sera in plastic squeezable dropping bottles, re-usable ...
Medicine Products: